Discovery of AZD2932, a new Quinazoline Ether Inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases

  • Bioorg Med Chem Lett. 2012 Jan 1;22(1):262-6. doi: 10.1016/j.bmcl.2011.11.019.
Patrick A Plé  1 ,  Frédéric Jung ,  Sue Ashton ,  Laurent Hennequin ,  Romuald Laine ,  Rémy Morgentin ,  Georges Pasquet ,  Sian Taylor
Affiliations
  • 1. AstraZeneca, Centre de Recherches, B.P. 1050, 51689 Reims Cedex 2, France. [email protected]
PMID: 22153662 DOI: 10.1016/j.bmcl.2011.11.019
Abstract

A new series of Quinazoline Ether Inhibitor which potently inhibits VEGFR-2 and PDGFR tyrosine Kinases is described here. In vitro, pharmacokinetics and in vivo evaluations led to the selection of AZD2932.

Products